Advances in neoadjuvant chemotherapy in soft tissue sarcomas

Area of Science:

• Oncology
• Medical Research

Background:

• Adjuvant chemotherapy for soft tissue sarcomas (STS) remains controversial.
• High-risk (AJCC stage III) extremity STS has a historically poor 5-year survival rate of approximately 50% with local therapy alone.
• There is a growing consensus favoring anthracycline- and ifosfamide-based regimens for this patient group.

Purpose of the Study:

• To review the rationale and evidence supporting the use of adjuvant chemotherapy in high-risk soft tissue sarcomas.
• To discuss the challenges and considerations in applying systemic therapy for rare and heterogeneous cancers like STS.
• To explore the basis for neoadjuvant chemotherapy in STS, drawing parallels with osteosarcoma research.

Main Methods:

• Review of published data, including meta-analyses of doxorubicin-based trials and prospective randomized data from the Italian Sarcoma Group.
• Analysis of the historical standard of care and survival rates for high-risk STS.
• Consideration of the limitations and toxicities of chemotherapy agents.

Main Results:

• Evidence from meta-analyses and prospective trials supports the use of epirubicin and ifosfamide-based regimens.
• The poor outcomes with local therapy alone highlight the need for systemic treatment integration.
• Challenges in interpreting negative studies for rare cancers are acknowledged.

Conclusions:

• The use of anthracycline- and ifosfamide-based adjuvant chemotherapy is increasingly supported for high-risk extremity STS.
• Careful patient selection is crucial to balance chemotherapy benefits against toxicity and quality of life.
• Neoadjuvant chemotherapy is proposed as a strategy, informed by osteosarcoma research, pending targeted therapies.